Form 4: CytomX Therapeutics Director Zhen Su Acquires 76,000 Stock Options

Director Zhen Su acquired 76,000 stock options in CytomX Therapeutics on March 20, 2024, according to a Form 4 filing.

Summary

• On March 20, 2024, Zhen Su, a director of CytomX Therapeutics, Inc., acquired 76,000 stock options at an exercise price of $2.27.
• The options vest monthly over three years, starting from March 20, 2024, and will be fully vested by the third anniversary, contingent upon continued service to the issuer.
• Following the transaction, Zhen Su directly owns 76,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction. The acquisition of stock options can be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The stock options will vest over the next three years, contingent on the director's continued service to the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This provides transparency to the market.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder confidence.

Key Dates